Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 12/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 6/20 | 0.37 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.37 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.37 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.37 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.37 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.37 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.37 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.37 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.37 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6795206 | 0.99 | F7 (0.53) | F7GRIN1GRIN2BSOS1ATP1A1 | |
| SCHEMBL8363605 | 0.88 | F7 (0.50) | F7GRIN1GRIN2BSOS1 | |
| SCHEMBL8363205 | 0.86 | F7 (0.57) | F7F3 | |
| SCHEMBL8363209 | 0.82 | F7 (0.58) | F7F3 | |
| SCHEMBL8360265 | 0.81 | F7 (0.65) | F7F3 | |
| SCHEMBL8362430 | 0.80 | F7 (0.56) | F7F3 | |
| SCHEMBL8363577 | 0.80 | F7 (0.73) | F7F3 | |
| SCHEMBL8360246 | 0.80 | F7 (0.73) | F7F3 | |
| SCHEMBL6796881 | 0.80 | F7 (0.49) | F7F3 | |
| SCHEMBL6794047 | 0.79 | F7 (0.70) | F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
| WO-2003028729-A2 | PRODRUGS OF SUBSTITUTED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, PLG | F7 54/4885GRIN1 4757/4885GRIN2B 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.